Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Safety and Efficacy of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF Plus Standard Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma

NCT04443010 is registered in ClinicalTrials.gov with Philogen S.p.A. as lead sponsor.

NCT NCT04443010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04443010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Safety and Efficacy of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF Plus Standard Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
Lead sponsor
Philogen S.p.A.
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 20, 2021
Completion date
December 31, 2026
Enrollment
226 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma